30 clinically diagnosed patients were randomly categorized into two equal groups. In Group A, Bodhi Vriksha Kashaya was administered orally in a dose of 40 ml twice a day. In Control Group i.e. Group B (Allopurinol) was given in the dose of 100 - 200 mg twice a day after breakfast/meal. Period of study was for 60 days along with a follow up at the interval of 15 days for one month. Assessment was done on symptoms of Hyperuricemia/Vatarakta as subjective parameter and serum uric acid as objective parameter. Obtained results were analysed statistically and significance of results were evaluated. Interventions were found to be significantly effective in reducing serum uric acid and in Kandu, Daha, Ruja, Toda, Sandhi Sotha and Stabdhata with p value < 0.001, more percentage relief was found in Daha, Ruja, Toda in patients treated with standard drug. After one month of treatment more sustained response was observed in patients treated with Bodhi Vriksha Kashaya. In Group A, only 23.07% show relapse to mild improvement after having moderate improvement. Bodhi Vriksha Kashaya Paan is quite promising, efficacious and safe treatment; its efficacy can be better interpreted by conducting a clinical trial on large sample size.
